Evaluation of QoL, tolerability and use of Zoladex 10,8 SafeSystem for advanced PCa - German IPEP trial
Study identifier:Zx-002
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Quality assurance project in patients with advanced prostate carcinoma - evaluation of tolerability, quality of life and usage of Zoladex 10,8 SafeSystem
Medical condition
Prostate Carcinoma
Phase
-
Healthy volunteers
No
Study drug
-
Sex
Male
Actual Enrollment
1950
Study type
Observational
Age
N/A
Date
Study Start Date: 01 Jun 2005
Primary Completion Date: -
Study Completion Date: -
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
H Brasch
AstraZeneca
